Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Reichmann, William M ^a   Yu, Yanni F ^b   Macaulay, Dendy ^a   Wu, Eric Q ^a   Nathan, Steven D ^c  

^a ANALYSIS GROUP   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Clinical outcomes; Forced vital capacity; Healthcare resource utilization; Idiopathic pulmonary fibrosis

Indexed keywords

ADULT; ARTICLE; DETERIORATION; DISEASE EXACERBATION; EMERGENCY CARE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE UTILIZATION; HOSPITAL UTILIZATION; HUMAN; INTENSIVE CARE; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; UNITED STATES; AGED; BIOPSY; DISEASE COURSE; HEALTH CARE PLANNING; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UTILIZATION; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; HEALTH RESOURCES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; VITAL CAPACITY;

EID: 84952657199     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0161-5     Document Type: Article

References (34)

1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810-6.
2. Raghu G, Chen S-Y, Yeh W-S, Maroni B, Li Q, Lee Y-C, et al. Idiopathic pulmonary fibrosis in Medicare beneficiaries: incidence, prevalence and survival. A41 Interstitial Lung Dis. Risk Factors Outcomes [Internet]. American Thoracic Society; 2014. A1514-A1514. [cited 2015 Feb 24]. Available from: http://www.atsjournals.org/doi/abs/ 10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1514.
3. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2007;176:636-43.
4. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140:221-9.
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
6. Pulmonary Fibrosis Foundation. Treatment [Internet]. Treat. PFF. [cited 2015 Jan 15]. Available from: http://www.pulmonaryfibrosis.org/life-with-pf/pulmonary-fibrosis-treatment-options.
7. U.S. Food and Drug Administration (FDA). FDA approves Ofev to treat idiopathic pulmonary fibrosis [Internet]. 2014 [cited 2015 Jun 30]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm.
8. U.S. Food and Drug Administration (FDA). FDA approves Esbriet to treat idiopathic pulmonary fibrosis [Internet]. 2014 [cited 2015 Jun 30]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418991.htm.
9. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-19.
10. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60:588-94.
11. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J. 2001;17:954-61.
12. Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15:829-35.
13. Wu N, Yu YF, Chuang C-C, Wang R, Benjamin NN, Coultas DB. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ. 2015;18:249-57.
14. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.
15. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King J, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963-7.
16. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830-6.
17. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538-42.
18. Jegal Y, Kim DS, Shim TS, Lim C-M, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639-44.
19. American Medical Association (AMA). AMA master list of pulmonologists. 2013.
20. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684-91.
21. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N -acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366:1968-77.
22. Naqvi SB, Kim HJ, Tomic R, Bhargava M, Perlman D. Acute exacerbation of idiopathic pulmonary fibrosis following lung biopsy: a case series. A41 Interstitial Lung Dis. Risk Factors Outcomes [Internet]. American Thoracic Society; 2014. A6585-A6585. [cited 2015 Mar 16]. Available from: http://www.atsjournals.org/doi/abs/ 10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A6585.
23. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543-8.
24. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005;127:171-7.
25. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. The clinical significance of 5 % change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res. 2011;12:93.
26. Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, et al. Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest. 2015.
27. Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord. 2010;27:103-10.
28. Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2015;147:173-9.
29. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746-52.
30. Whelan TPM, Dunitz JM, Kelly RF, Edwards LB, Herrington CS, Hertz MI, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2005;24:1269-74.
31. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128:2393-9.
32. Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40:93-100.
33. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
34. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.